2015
DOI: 10.2217/pgs.15.106
|View full text |Cite
|
Sign up to set email alerts
|

A Glutamatergic Network Mediates Lithium Response in Bipolar Disorder as Defined by Epigenome Pathway Analysis

Abstract: This pharmacoepigenomic regulatory pathway is located in the same brain regions that exhibit tissue volume loss in bipolar disorder. Although in silico analysis requires biological validation, the approach provides value for identification of candidate variants that may be used in pharmacogenomic testing to identify bipolar patients likely to respond to lithium.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
28
0
3

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 39 publications
(31 citation statements)
references
References 148 publications
0
28
0
3
Order By: Relevance
“…Moreover, in this mouse model the correlation between GSK3, behavior, dendritic spine and glutamatergic synapse phenotypes supports the notion that spines and glutamatergic synapses are critical biological substrates underlying lithium-responsive psychiatric conditions. (53-55). …”
Section: Discussionmentioning
confidence: 99%
“…Moreover, in this mouse model the correlation between GSK3, behavior, dendritic spine and glutamatergic synapse phenotypes supports the notion that spines and glutamatergic synapses are critical biological substrates underlying lithium-responsive psychiatric conditions. (53-55). …”
Section: Discussionmentioning
confidence: 99%
“…Finally, cortical pyramidal neurons from a mouse line mutant for the neuronally expressed Wnt/β-catenin pathway activator and DISC1 partner Dixdc1 have reduced dendritic spine and excitatory synapse density correlating with phenotypes in the affective domain (behavioral despair) and social domain (reciprocal social interaction); administration of either lithium or a selective GKS3 inhibitor corrects both the neurodevelopmental and behavioral phenotypes in these animals [343]. This supports that a major neurodevelopmental/neuroplastic target of lithium - and of other psychiatric drugs that either directly or indirectly modulate GSK3 - is the formation, stability, and/or turnover of dendritic spines and glutamatergic synapses [325,344,345]. The same study also provided evidence supporting a “goldilocks principle” for Wnt signaling in these processes at the dendritic spine and synapse, showing that either too much or too little signal pathway activation is similarly deleterious [343].…”
Section: Concluding Remarks: Therapeutic Considerationsmentioning
confidence: 90%
“…Lithium is commonly used for the treatment of mood disorders and may therefore regulate proteins genetically linked to pathophysiology such as ANK3. Analysis of functional SNPs from GWAS data suggest that AnkG may be involved in the lithium response (33). Lithium has been shown to rescue some BD-related behavioral deficits in different Ank3 KO mouse model (35,41,42), suggesting it can alleviate symptoms of mouse models with AnkG loss of function.…”
Section: Discussionmentioning
confidence: 99%